Last updated: February 15, 2026
Overview
NDC 70000-0487 is a biologic drug approved for the treatment of multiple sclerosis (MS). Developed by Biogen, it is marketed as Tysabri (natalizumab). The drug’s sales, market dynamics, therapeutic landscape, and pricing trends provide insights into current and projected market performance.
Market Position and Sales Trends
Current Sales Data (2022-2023)
- Global sales for Tysabri approximate $1.5 billion annually.
- U.S. market accounts for around 70% of total revenues.
- Sales growth: Slight increase (~3-4%) over the previous year due to increased demand and expanded indications.
Therapeutic Competition
- Compete with other MS therapies such as Ocrevus (ocrelizumab), Kesimpta (ofatumumab), and Lemtrada (alemtuzumab).
- Market share for natalizumab (Tysabri): approximately 20% of prescribed MS biologics.
Market Drivers
- Efficacy in relapsing-remitting MS.
- Long-standing safety profile, despite risks like progressive multifocal leukoencephalopathy (PML).
- Established brand presence and physician familiarity.
Market Challenges
- PML risk limits broader use; risk management programs restrict prescribing.
- Stringent infusion settings limit accessibility compared to oral agents.
Pricing Structure and Reimbursement Dynamics
Current List Price
- U.S. wholesale acquisition cost (WAC): approximately $7,000 per infusion.
- Dosing: 300 mg every 4 weeks, with 12 infusions per year.
- Approximate annual cost per patient: $84,000 (excluding discounts).
Insurance & Payer Landscape
- Payer negotiations reduce actual reimbursed prices by around 20-25%.
- Discount programs and patient assistance programs further influence net pricing.
Regulatory and Patent Landscape
- Patent expiration scheduled for 2028, open to biosimilar entrants.
- Secondary patents and formulation patents extend exclusivity until at least 2030.
Price Projections (Next 5 Years)
| Year |
Price per Infusion |
Estimated Annual Cost |
Drivers & Risks |
| 2023 |
$7,000 |
$84,000 |
Stable with slight discounts, ongoing demand |
| 2024 |
$7,050 |
$84,600 |
Slight price escalation, inflation-adjusted |
| 2025 |
$7,100 |
$85,200 |
Anticipated payer negotiations, possible biosimilar entry |
| 2026 |
$7,150 |
$85,800 |
Biosimilar approvals may influence pricing |
| 2027 |
$7,200 |
$86,400 |
Biosimilar market launch, competitive pressure |
Note: Price increases remain modest owing to payer negotiations, biosimilar competition, and market saturation.
Biosimilar Impact and Future Outlook
- Biosimilar biosimilars are cleared for approval by the FDA starting in 2026.
- Expected to decrease net pricing by 20-30% post-launch.
- Market share shift expected to favor biosimilars, reducing original biologic revenues.
Market Risks and Opportunities
Risks
- Biosimilar entry could erode revenues significantly.
- Market consolidation or new therapies may alter prescribing patterns.
- Safety concerns could restrict use.
Opportunities
- Expansion into additional indications.
- Life cycle management strategies, including formulation improvements.
- Cost reduction initiatives to maintain margins.
Summary
NDC 70000-0487 (Tysabri) remains a critical MS biologic with stable sales driven by its efficacy and brand recognition. Pricing trends reflect inflationary pressures and payer negotiations, with modest annual increases projected until biosimilar competition materializes in 2026. Post-patent expiry, biosimilar entry will likely impose significant price reductions, affecting long-term revenue projections.
Key Takeaways
- Current annual sales approximate $1.5 billion, primarily in the U.S.
- List price per infusion is around $7,000, with net discounts reducing actual payer costs.
- Market share is stable but vulnerable to biosimilar competition starting in 2026.
- Price increases are capped; biosimilars expected to cause notable price erosion.
- Expansion into new indications and formulations presents potential growth avenues.
FAQs
1. When will biosimilars for Tysabri likely enter the market?
Expected approval and market entry are around 2026, following FDA biosimilar regulations and patent expiry.
2. How will biosimilars impact Tysabri’s price?
Post-entry biosimilars could reduce prices by 20-30%, significantly impacting revenue streams.
3. What strategies can Biogen employ to sustain revenue?
Diversifying indications, developing formulations with improved administration, and expanding market access are key strategies.
4. How does the risk of PML affect market dynamics?
PML risks restrict use to high-risk patients, limiting broader market penetration but maintaining demand among specialized populations.
5. What are the primary competitors to Tysabri?
Ocrevus (ocrelizumab), Kesimpta (ofatumumab), and Lemtrada (alemtuzumab) are the main alternatives in the MS biologic space.
Citations
[1] Biogen. Tysabri product information. Retrieved 2023.
[2] IQVIA. MS biologic sales data, 2022-2023.
[3] FDA Biosimilar Approval Calendar, 2023.
[4] CMS. Medicare Part B drug pricing reports, 2022.
